These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 21164028)

  • 1. Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients.
    Goodkin DA; Fuller DS; Robinson BM; Combe C; Fluck R; Mendelssohn D; Akizawa T; Pisoni RL; Port FK
    J Am Soc Nephrol; 2011 Feb; 22(2):358-65. PubMed ID: 21164028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anemia Evaluation and Erythropoietin Dose Requirement Among Hemodialysis Patients: a Multicenter Study.
    Nafar M; Samavat S; Khoshdel A; Alipour-Abedi B
    Iran J Kidney Dis; 2017 Jan; 11(1):56-65. PubMed ID: 28174354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion.
    Collins AJ; Monda KL; Molony JT; Li S; Gilbertson DT; Bradbury BD
    Am J Kidney Dis; 2014 Jun; 63(6):997-1006. PubMed ID: 24315770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythropoietin therapy, hemoglobin targets, and quality of life in healthy hemodialysis patients: a randomized trial.
    Foley RN; Curtis BM; Parfrey PS
    Clin J Am Soc Nephrol; 2009 Apr; 4(4):726-33. PubMed ID: 19339412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of Hemoglobin Cycling and Its Clinical Impact on Outcomes in Thai End-Stage Renal Disease Patients Treated with Hemodialysis and Erythropoiesis-Stimulating Agent.
    Thanakitcharu P; Jirajan B
    J Med Assoc Thai; 2016 Feb; 99 Suppl 2():S28-37. PubMed ID: 27266213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current management of anemia in adult hemodialysis patients with end-stage renal disease.
    Frankenfield DL; Johnson CA
    Am J Health Syst Pharm; 2002 Mar; 59(5):429-35. PubMed ID: 11887409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of mean weekly epoetin alfa dose with mortality risk in a retrospective cohort study of Medicare hemodialysis patients.
    Weinhandl ED; Gilbertson DT; Collins AJ
    Am J Nephrol; 2011; 34(4):298-308. PubMed ID: 21829009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemoglobin of 12 g/dl and above is not associated with increased cardiovascular morbidity in children on hemodialysis.
    Rheault MN; Molony JT; Nevins T; Herzog CA; Chavers BM
    Kidney Int; 2017 Jan; 91(1):177-182. PubMed ID: 27865440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Erythropoietin-Stimulating Agent Responsiveness with Mortality in Hemodialysis and Peritoneal Dialysis Patients.
    Bae MN; Kim SH; Kim YO; Jin DC; Song HC; Choi EJ; Kim YL; Kim YS; Kang SW; Kim NH; Yang CW; Kim YK
    PLoS One; 2015; 10(11):e0143348. PubMed ID: 26588085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hemoglobin levels in hemodialysis patients treated with epoetin: a Brazilian experience].
    Ammirati AL; Watanabe R; Aoqui C; Draibe SA; Carvalho AB; Abensur H; Drumond SS; Moreira J; Bevilacqua JL; Silva AC; Tatsch F; Canziani ME
    Rev Assoc Med Bras (1992); 2010; 56(2):209-13. PubMed ID: 20498997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients.
    Ofsthun N; Labrecque J; Lacson E; Keen M; Lazarus JM
    Kidney Int; 2003 May; 63(5):1908-14. PubMed ID: 12675871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Opatija study: observation of hemodialysis patients and titration of CERA dose just switched from another erythropoiesis stimulating agent].
    Jelić I; Lovcić V; Kurtović I; Josipović M; Havranek Z; Kostić L; Racki S
    Acta Med Croatica; 2012 Jul; 66(3):157-64. PubMed ID: 23441529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol.
    Strippoli GF;
    Trials; 2010 Jun; 11():70. PubMed ID: 20534124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dL.
    Bradbury BD; Danese MD; Gleeson M; Critchlow CW
    Clin J Am Soc Nephrol; 2009 Mar; 4(3):630-7. PubMed ID: 19261826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan.
    Fukuma S; Yamaguchi T; Hashimoto S; Nakai S; Iseki K; Tsubakihara Y; Fukuhara S
    Am J Kidney Dis; 2012 Jan; 59(1):108-16. PubMed ID: 21890255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anemia Treatment by Erythropoiesis-stimulating Agents during the 6 Months before the Initiation of Hemodialysis: Comparison of Darbepoetin Alfa and Continuous Erythropoietin Receptor Activator.
    Yoshida T; Hayashi M
    Keio J Med; 2017 Sep; 66(3):44-50. PubMed ID: 27990008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemoglobin levels and erythropoietin doses in hemodialysis and peritoneal dialysis patients in the United States.
    Snyder JJ; Foley RN; Gilbertson DT; Vonesh EF; Collins AJ
    J Am Soc Nephrol; 2004 Jan; 15(1):174-9. PubMed ID: 14694170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An international observational study suggests that artificial intelligence for clinical decision support optimizes anemia management in hemodialysis patients.
    Barbieri C; Molina M; Ponce P; Tothova M; Cattinelli I; Ion Titapiccolo J; Mari F; Amato C; Leipold F; Wehmeyer W; Stuard S; Stopper A; Canaud B
    Kidney Int; 2016 Aug; 90(2):422-429. PubMed ID: 27262365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy.
    Foley RN; Curtis BM; Parfrey PS
    Clin J Am Soc Nephrol; 2008 Nov; 3(6):1669-75. PubMed ID: 18922988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.